S1‐Guideline Sebaceous Carcinoma.
S1 guideline
cancer
oncology
sebaceous carcinoma
sebaceous gland
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
28 Apr 2024
28 Apr 2024
Historique:
received:
08
01
2024
accepted:
19
02
2024
medline:
29
4
2024
pubmed:
29
4
2024
entrez:
28
4
2024
Statut:
aheadofprint
Résumé
Sebaceous gland carcinomas are rare malignant cutaneous adnexal tumors with sebocytic differentiation. The typical predilection area is the head and neck region, where sebaceous gland carcinomas are the most common malignant adnexal tumors of the skin. According to their localization a distinction is made between periocular and extraocular sebaceous gland carcinomas. Muir-Torre syndrome (MTS) should always be ruled out if it is suspected. In terms of prognosis, sebaceous gland carcinomas are potentially aggressive tumors with a clear tendency to recur and metastasize. Only small extraocular sebaceous gland carcinomas that have been completely resected have a very good prognosis. Sebaceous gland carcinomas most frequently metastasize lymphogenously to regional or distant lymph nodes; organ metastasis occurs less frequently. Periocular sebaceous gland carcinomas have a higher metastasis rate (up to 15%) than extraocular sebaceous gland carcinomas (up to 2%). Complete micrographically controlled surgery (MCS) of the primary tumor is the therapy of first choice, regardless of periocular or extraocular localization. Adjuvant or therapeutic radiotherapy may be considered. There is currently no established standard therapy for advanced, inoperable, or metastatic sebaceous gland carcinomas. Local procedures and systemic therapies such as chemotherapy or immunotherapy can be considered. The procedure should be determined individually by an interdisciplinary tumor board. Close follow-up care is recommended for these potentially aggressive carcinomas.
Types de publication
English Abstract
Journal Article
Langues
spa
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
Références
North JP, Golovato J, Vaske CJ, et. al. Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma. Nat Commun. 2018;9:1894.
Jandali DB, Ganti A, Al‐Khudari S, et al. Prognostic factors and survival outcomes for head and neck cutaneous adnexal cancers. Am J Otolaryngol. 2019;40:110‐114.
Lim VS, Amrith S. Declining incidence of eyelid cancers in Singapore over 13 years: population‐based data from 1996 to 2008. Br J Ophthalmol. 2012;96:1462‐1465.
Tripathi R, Chen Z, Li L, Bordeaux JS. Incidence and survival of sebaceous carcinoma in the United States. J Am Acad Dermatol. 2016;75:1210‐1215.
Wu A, Rajak SN, Huilgol SC, James C, Selva D. Cutaneous sebaceous carcinoma. Australas J Dermatol. 2020;61:e283‐e292.
Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer. 2009;115:158‐165.
Kazakov DV. Cutaneous adnexal tumors. Lippincott Williams & Wilkins, Philadelphia, Pa.; London, 2012.
Holterhues C, Vries E, Louwman MW, et al. Incidence and trends of cutaneous malignancies in the Netherlands, 1989–2005. J Invest Dermatol. 2010;130:1807‐1812.
Owen JL, Kibbi N, Worley B, et al. Sebaceous carcinoma: evidence‐based clinical practice guidelines. Lancet Oncol. 2019;20:e699‐e714.
Kazakov DV, Calonje E, Zelger B, et al. Sebaceous carcinoma arising in nevus sebaceus of Jadassohn: a clinicopathological study of five cases. Am J Dermatopathol. 2007;29:242‐248.
Tetzlaff MT, Singh RR, Seviour EG, et al. Next‐generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. J Pathol. 2016;240:84‐95.
Sargen MR, Cahoon EK, Lynch CF, et al. Sebaceous Carcinoma Incidence and Survival Among Solid Organ Transplant Recipients in the United States, 1987–2017. JAMA Dermatol. 2020;156:1307‐1314.
Sargen MR, Starrett GJ, Engels EA, et al. Sebaceous carcinoma epidemiology and genetics: Emerging concepts and clinical implications for screening, prevention, and treatment. Clin Cancer Res. 2020.27:389‐393.
Sargen MR, Mai ZM, Engels EA, et al. Ambient Ultraviolet Radiation and Sebaceous Carcinoma Incidence in the United States, 2000–2016. JNCI Cancer Spectr. 2020;4:20.pkaa020. [Last accessed on February 3, 2024]
Na HY, Choe JY, Shin SA, et al. Proposal of a Provisional Classification of Sebaceous Carcinoma Based on Hormone Receptor Expression and HER2 Status. Am J Surg Pathol. 2016;40:1622‐1630.
Tetzlaff MT, Curry JL, Ning J, et al. Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV‐Driven and Virus‐Negative Tumors Arise through Nonoverlapping Molecular‐Genetic Alterations. Clin Cancer Res. 2019;25:1280‐1290.
Stagner AM, Afrogheh AH, Jakobiec FA, et al. p16 Expression Is Not a Surrogate Marker for High‐Risk Human Papillomavirus Infection in Periocular Sebaceous Carcinoma. Am J Ophthalmol. 2016;170:168‐175.
Cerroni L, Garbe C, Metze D, et al. Histopathologie der Haut. 2. Auflage Edition. Springer, Berlin; Heidelberg, 2016.
Birnbaum RY, Zvulunov A, Hallel‐Halevy D, et al. Seborrhea‐like dermatitis with psoriasiform elements caused by a mutation in ZNF750, encoding a putative C2H2 zinc finger protein. Nat Genet. 2006;38:749‐751.
Xu S, Moss TJ, Laura Rubin M, et al. Whole‐exome sequencing for ocular adnexal sebaceous carcinoma suggests PCDH15 as a novel mutation associated with metastasis. Mod Pathol. 2020;33:1256‐1263.
Chao AN, Shields CL, Krema H, Shields JA. Outcome of patients with periocular sebaceous gland carcinoma with and without conjunctival intraepithelial invasion. Ophthalmology. 2001;108:1877‐1883.
Kivelä T, Asko‐Seljavaara S, Pihkala U, et al. Sebaceous carcinoma of the eyelid associated with retinoblastoma. Ophthalmology. 2001;108:1124‐1128.
Song A, Carter KD, Syed NA, et al. Sebaceous cell carcinoma of the ocular adnexa: clinical presentations, histopathology, and outcomes. Ophthalmic Plast Reconstr Surg. 2008; 24: 194‐200.
Imko‐Walczuk B, Kryś A, Lizakowski S, et al. Sebaceous carcinoma in patients receiving long‐term immunosuppresive treatment: case report and literature review. Transplant Proc. 2014;46:2903‐2907.
Lanoy E, Dores GM, Madeleine MM, et al. Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States. Aids. 2009;23:385‐393.
Brewer JD, Shanafelt TD, Call TG, et al. Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukemia. Int J Dermatol. 2015;54:e287‐293.
Moore RF, Zhang XR, Allison DB, et al. High‐risk human papillomavirus and ZEB1 in ocular adnexal sebaceous carcinoma. J Cutan Pathol. 2021;48:1027‐1033.
Gao H, Tang L, Lin J, et al. Detection of Epstein‐Barr Virus in 130 Cases of Eyelid Sebaceous Gland Carcinoma Using In Situ Hybridization. J Ophthalmol. 2020;2020:7354275.
Tanahashi J, Kashima K, Daa T, et al. Merkel cell carcinoma co‐existent with sebaceous carcinoma of the eyelid. J Cutan Pathol. 2009;36:983‐986.
Rao NA, Hidayat AA, McLean IW, Zimmerman LE. Sebaceous carcinomas of the ocular adnexa: A clinicopathologic study of 104 cases, with five‐year follow‐up data. Hum Pathol. 1982;13:113‐122.
Weltgesundheitsorganisation. WHO classification of skin tumours. 4th edition Edition. International Agency for Research on Cancer, Lyon, 2018. [Last accessed on January 15, 2024]
Boaz RJ, Phukan C, Mandeep S, Devasia A. Sebaceous carcinoma of the penis: As aggressive as it is rare. Urol Ann. 2019;11:226‐228.
Hanaka T, Makihara K, Hachiya Y, Mukae H. Primary lung sebaceous carcinoma. Intern Med. 2015;54:351‐352.
Oshiro H, Iwai T, Hirota M, et al. Primary sebaceous carcinoma of the tongue. Med Mol Morphol. 2010;43:246‐252.
Pusiol T, Morichetti D, Zorzi MG. Sebaceous carcinoma of the vulva: critical approach to grading and review of the literature. Pathologica. 2011;103:64‐67.
Švajdler M, Baník P, Poliaková K, et al. Sebaceous carcinoma of the breast: report of four cases and review of the literature. Pol J Pathol. 2015;66:142‐148.
Muqit MM, Foot B, Walters SJ, et al. Observational prospective cohort study of patients with newly‐diagnosed ocular sebaceous carcinoma. Br J Ophthalmol. 2013;97:47‐51.
Cheng CY, Chuang YH. Pigmented sebaceous carcinoma: dermatoscopic features of a new case. Eur J Dermatol. 2020;30:58‐60.
Satomura H, Ogata D, Arai E, Tsuchida T. Dermoscopic features of ocular and extraocular sebaceous carcinomas. J Dermatol. 2017;44:1313‐1316.
While B, Salvi S, Currie Z, et al. Excision and delayed reconstruction with paraffin section histopathological analysis for periocular sebaceous carcinoma. Ophthalmic Plast Reconstr Surg. 2014;30:105‐109.
Iacobelli J, Harvey NT, Wood BA. Sebaceous lesions of the skin. Pathology. 2017;49:688‐697.
Alsaad KO, Obaidat NA, Ghazarian D. Skin adnexal neoplasms–part 1: an approach to tumours of the pilosebaceous unit. J Clin Pathol. 2007;60:129‐144.
Pereira PR, Odashiro AN, Rodrigues‐Reyes AA, et al. Histopathological review of sebaceous carcinoma of the eyelid. J Cutan Pathol. 2005;32:496‐501.
Sa HS, Rubin ML, Xu S, et al. Prognostic factors for local recurrence, metastasis and survival for sebaceous carcinoma of the eyelid: observations in 100 patients. Br J Ophthalmol. 2019;103:980‐984.
Kibbi N, Worley B, Owen JL, et al. Sebaceous carcinoma: controversies and their evidence for clinical practice. Arch Dermatol Res. 2020;312:25‐31.
Tryggvason G, Bayon R, Pagedar NA. Epidemiology of sebaceous carcinoma of the head and neck: implications for lymph node management. Head Neck. 2012;34:1765‐1768.
Hsia Y, Yeh CY, Wei YH, et al. Eyelid sebaceous carcinoma: Validation of the 8th edition of the American Joint Committee on cancer T staging system and the prognostic factors for local recurrence, nodal metastasis, and survival. Eye (Lond). 2019;33:887‐895.
Kaliki S, Gupta A, Ali MH, et al. Prognosis of eyelid sebaceous gland carcinoma based on the tumor (T) category of the American Joint Committee on Cancer (AJCC) classification. Int Ophthalmol. 2016;36:681‐690.
Lee IJ, Koh JY. Impact of clinicopathologic factors on survival in patients with sebaceous carcinoma of the eyelid ‐ a population‐based analysis. Orbit. 2019;38:261‐268.
Wittekind C. TNM ‐ Klassifikation maligner Tumoren Achte Auflage, korrigierter Nachdruck 2020 mit allen Ergänzungen der UICC aus den Jahren 2017 bis 2019 Edition. Wiley‐VCH, Weinheim, 2020.
American Joint Committee on C. AJCC cancer staging manual. Eighth edition, corrected at 3rd printing Edition. AJCC, American Joint Committee on Cancer, Chicago, IL, 2017.
South CD, Hampel H, Comeras I, et al. The frequency of Muir‐Torre syndrome among Lynch syndrome families. J Natl Cancer Inst. 2008;100:277‐281.
Gay JT, Troxell T, Gross GP. Muir‐Torre Syndrome. StatPearls. Treasure Island (FL): StatPearls. 2020. [Last accessed on February 10, 2022]
John AM, Schwartz RA. Muir‐Torre syndrome (MTS): An update and approach to diagnosis and management. J Am Acad Dermatol. 2016;74:558‐566.
Ponti G, Ponz de Leon M. Muir‐Torre syndrome. Lancet Oncol. 2005;6:980‐987.
Tripathi R, Bordeaux JS. Impact of Muir‐Torre Syndrome on Survival in Patients With Sebaceous Carcinoma: A SEER Population‐Based Study. Dermatol Surg. 2019;45:148‐149.
Nagel P, Muller V, Utikal J. Management von malignen Adnextumoren der Haut. Hautarzt. 2021;72:619‐632.
Roberts ME, Riegert‐Johnson DL, Thomas BC, et al. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir‐Torre variant of Lynch syndrome. Genet Med. 2014;16:711‐716.
Cohen PR, Kohn SR, Kurzrock R. Association of sebaceous gland tumors and internal malignancy: the Muir‐Torre syndrome. Am J Med. 1991;90:606‐613.
Knackstedt T, Samie FH. Sebaceous Carcinoma: A Review of the Scientific Literature. Curr Treat Options Oncol. 2017;18:47.
Kyllo RL, Brady KL, Hurst EA. Sebaceous carcinoma: review of the literature. Dermatol Surg. 2015;41:1‐15.
Zhou C, Wu F, Chai P, et al. Mohs micrographic surgery for eyelid sebaceous carcinoma: A multicenter cohort of 360 patients. J Am Acad Dermatol. 2019;80:1608‐1617.e1.
Desiato VM, Byun YJ, Nguyen SA, Thiers BH, Day TA. Sebaceous Carcinoma of the Eyelid: A Systematic Review and Meta‐Analysis. Dermatol Surg. 2021;47:104‐110.
Lally SE, Rao R, Shields JA, Shields CL. Comparison of posterior lamellar resection versus lumpectomy for initial management of localized tarsal conjunctival sebaceous carcinoma in 54 cases. Indian J Ophthalmol. 2018;66:1295‐1300.
Leivo T, Sarmela J, Enckell‐Aaltonen M, Dafgård Kopp E, Schmitt C, Toft PB, Sigurdsson H, Uusitalo M. Nordic treatment practices survey and consensus for treatment of eyelid sebaceous carcinoma. BMC Ophthalmol. 2020;20:103.
Gerring RC, Ott CT, Curry JM, et al. Orbital exenteration for advanced periorbital non‐melanoma skin cancer: prognostic factors and survival. Eye (Lond). 2017;31:379‐388.
Takagawa Y, Tamaki W, Suzuki S, et al. Radiotherapy for localized sebaceous carcinoma of the eyelid: a retrospective analysis of 83 patients. J Radiat Res. 2019;60:622‐629.
Yen MT, Tse DT, Wu X, Wolfson AH. Radiation therapy for local control of eyelid sebaceous cell carcinoma: report of two cases and review of the literature. Ophthalmic Plast Reconstr Surg. 2000;16:211‐215.
Hata M, Koike I, Omura M, et al. Noninvasive and curative radiation therapy for sebaceous carcinoma of the eyelid. Int J Radiat Oncol Biol Phys. 2012;82:605‐611.
Li F, Stewart RD, Finger PT. Interstitial Brachytherapy for Orbital Sebaceous Carcinoma. Ophthalmic Plast Reconstr Surg. 2021;37:e215‐e217.
Azad S, Choudhary V. Treatment results of high dose rate interstitial brachytherapy in carcinoma of eye lid. J Cancer Res Ther. 2011;7:157‐161.
Takagawa Y, Murakami N, Suzuki S, et al. High‐dose‐rate interstitial brachytherapy for a bulky sebaceous carcinoma of the eyelid: A case report. Clin Case Rep. 2019;7:1844‐1848.
Chang AY, Miller CJ, Elenitsas R, et al. Management Considerations in Extraocular Sebaceous Carcinoma. Dermatol Surg. 2016; 42(1):57‐65.
Lisman RD, Jakobiec FA, Small P. Sebaceous carcinoma of the eyelids. The role of adjunctive cryotherapy in the management of conjunctival pagetoid spread. Ophthalmology. 1989;96:1021‐1026.
Monai N, Tanabu R, Gonome T, et al. Intraoperative Adjunctive Mitomycin C and Cryotherapy for Recurrent Conjunctival Papillary Sebaceous Carcinoma. Case Rep Ophthalmol. 2018;9:221‐226.
Rudkin AK, Muecke JS. Mitomycin‐C as adjuvant therapy in the treatment of sebaceous gland carcinoma in high‐risk locations. Clin Exp Ophthalmol. 2009;37:352‐356.
Russell HC, Chadha V, Lockington D, Kemp EG. Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10‐year review of treatment outcomes and complications. Br J Ophthalmol. 2010;94:1316‐1321.
Shields CL, Naseripour M, Shields JA, Eagle RC, Jr. Topical mitomycin‐C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland carcinoma. Ophthalmology. 2002;109:2129‐2133.
Xu Y, Li F, Jia R, Fan X. Updates on the clinical diagnosis and management of ocular sebaceous carcinoma: a brief review of the literature. Onco Targets Ther. 2018;11:3713‐3720.
Karp CL, Galor A, Chhabra S, et al. Subconjunctival/perilesional recombinant interferon α2b for ocular surface squamous neoplasia: a 10‐year review. Ophthalmology. 2010;117:2241‐2246.
Karp CL, Moore JK, Rosa RH, Jr. Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha‐2b. Ophthalmology. 2001;108:1093‐1098.
Midena E, Angeli CD, Valenti M, et al. Treatment of conjunctival squamous cell carcinoma with topical 5‐fluorouracil. Br J Ophthalmol. 2000;84:268‐272.
Borgognoni L, Pescitelli L, Gerlini G, et al. Efficacy of Electrochemotherapy in the Treatment of Cutaneous Melanoma Metastases and Rare Non‐melanoma Skin Cancer. Anticancer Res. 2020;40:6485‐6492.
Ribero S, Baduel ES, Brizio M, et al. Metastatic sebaceous cell carcinoma, review of the literature and use of electrochemotherapy as possible new treatment modality. Radiol Oncol. 2016;50:308‐312.
Gogia A, Pushker N, Sen S, Bakhshi S. Avoidance of exenteration in orbital sebaceous gland carcinoma with neoadjuvant chemotherapy. Graefes Arch Clin Exp Ophthalmol. 2013;251:2479‐2480.
Husain A, Blumenschein G, Esmaeli B. Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol. 2008;47:276‐279.
Joshi P, Joshi A, Norohna V, et al. Sebaceous carcinoma and systemic chemotherapy. Indian J Med Paediatr Oncol. 2012;33:239‐241.
Jung YH, Woo IS, Kim MY, et al. Palliative 5‐fluorouracil and cisplatin chemotherapy in recurrent metastatic sebaceous carcinoma: Case report and literature review. Asia Pac J Clin Oncol. 2016;12:e189‐193.
Kaliki S, Ayyar A, Nair AG, et al. Neoadjuvant Systemic Chemotherapy in the Management of Extensive Eyelid Sebaceous Gland Carcinoma: A study of 10 Cases. Ophthalmic Plast Reconstr Surg. 2016;32:35‐39.
Koyama S, Honda T, Hayano T, et al. [A case of lung metastasis from Meibomian gland carcinoma of eyelid with effective chemotherapy]. Gan To Kagaku Ryoho. 1994;21:2809‐2812.
Kumar V, Xu Y. Unusual presentation of metastatic sebaceous carcinoma and its response to chemotherapy: is genotyping a right answer for guiding chemotherapy in rare tumours? Curr Oncol. 2015;22:e316‐319.
Murthy R, Honavar SG, Burman S, et al. Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis. Ophthalmic Plast Reconstr Surg. 2005;21:307‐309.
Orcurto A, Gay BE, Sozzi WJ, et al. Long‐Term Remission of an Aggressive Sebaceous Carcinoma following Chemotherapy. Case Rep Dermatol. 2014;6:80‐84.
Osada S, Ueno T, Inai S, et al. Sebaceous carcinoma of the nose with a regional metastasis following false‐negative sentinel lymph node biopsy. Acta Derm Venereol. 2011;91:367‐368.
Paschal BR, Bagley CS. Sebaceous gland carcinoma of the eyelid: complete response to sequential combination chemotherapy. N C Med J. 1985;46:473‐474.
Priyadarshini O, Biswas G, Biswas S, et al. Neoadjuvant chemotherapy in recurrent sebaceous carcinoma of eyelid with orbital invasion and regional lymphadenopathy. Ophthalmic Plast Reconstr Surg. 2010;26:366‐368.
De Leo A, Innocenzi D, Onesti MG, et al. Extraocular sebaceous carcinoma in Muirr Torre Syndrome with unfavorable prognosis. Cancer Chemother Pharmacol. 2006;58:842‐844.
Kandl TJ, Sagiv O, Curry JL, et al. High expression of PD‐1 and PD‐L1 in ocular adnexal sebaceous carcinoma. Oncoimmunology. 2018;7:e1475874.
Domingo‐Musibay E, Murugan P, Giubellino A, et al. Near complete response to Pembrolizumab in microsatellite‐stable metastatic sebaceous carcinoma. J Immunother Cancer. 2018;6:58.
Kodali S, Tipirneni E, Gibson PC, et al. Carboplatin and Pembrolizumab Chemoimmunotherapy Achieves Remission in Recurrent, Metastatic Sebaceous Carcinoma. Ophthalmic Plast Reconstr Surg. 2018;34:e149‐e151.
Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA‐4 blockade in metastatic melanoma. Science. 2015;350:207‐211.
Saliba M, Shaheen M, Hajj RE, et aI. PD‐L1 expression in sebaceous carcinomas. Cancer Immunol Immunother. 2021;70:1907‐1915.
Leiter U, Heppt MV, Steeb T, et al. S3‐Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ ‐ Kurzfassung, Teil 2: Epidemiologie, chirurgische und systemische Therapie des Plattenepithelkarzinoms, Nachsorge, Prävention und Berufskrankheit. J Dtsch Dermatol Ges. 2020;18:400‐413.